33.34
price up icon1.18%   0.39
after-market After Hours: 33.34
loading
Ionis Pharmaceuticals Inc stock is traded at $33.34, with a volume of 1.08M. It is up +1.18% in the last 24 hours and up +4.81% over the past month. Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$32.95
Open:
$32.88
24h Volume:
1.08M
Relative Volume:
0.68
Market Cap:
$5.30B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-13.66
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
-0.21%
1M Performance:
+4.81%
6M Performance:
-21.99%
1Y Performance:
-20.92%
1-Day Range:
Value
$32.88
$33.48
1-Week Range:
Value
$32.32
$34.74
52-Week Range:
Value
$30.23
$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
Name
Ionis Pharmaceuticals Inc
Name
Phone
(760) 931-9200
Name
Address
2855 GAZELLE COURT, CARLSBAD, CA
Name
Employee
927
Name
Twitter
@ionispharma
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IONS's Discussions on Twitter

Compare IONS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IONS
Ionis Pharmaceuticals Inc
33.34 5.30B 803.07M -358.81M -374.21M -2.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-02-24 Downgrade BMO Capital Markets Outperform → Market Perform
Jul-24-24 Upgrade Leerink Partners Market Perform → Outperform
Jul-16-24 Resumed Jefferies Buy
Jun-14-24 Upgrade Bernstein Underperform → Mkt Perform
Apr-10-24 Upgrade Wolfe Research Peer Perform → Outperform
Jan-02-24 Upgrade BofA Securities Neutral → Buy
Oct-23-23 Upgrade BofA Securities Underperform → Neutral
Sep-29-23 Initiated Raymond James Strong Buy
Jul-31-23 Upgrade Citigroup Neutral → Buy
Jun-07-23 Resumed Piper Sandler Overweight
May-04-23 Upgrade Citigroup Sell → Neutral
Mar-21-23 Initiated Bernstein Underperform
Dec-21-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-22 Resumed Morgan Stanley Overweight
Jul-18-22 Resumed Oppenheimer Outperform
Mar-31-22 Resumed Piper Sandler Overweight
Mar-01-22 Initiated Citigroup Sell
Mar-01-22 Initiated Guggenheim Buy
Feb-01-22 Downgrade BofA Securities Buy → Underperform
Dec-14-21 Upgrade William Blair Mkt Perform → Outperform
May-07-21 Upgrade UBS Sell → Neutral
Mar-01-21 Upgrade Barclays Underweight → Equal Weight
Dec-16-20 Initiated UBS Sell
Dec-15-20 Upgrade Cowen Market Perform → Outperform
Sep-14-20 Resumed JP Morgan Neutral
Sep-02-20 Initiated The Benchmark Company Hold
Jun-01-20 Resumed Oppenheimer Outperform
May-13-20 Initiated RBC Capital Mkts Outperform
Mar-05-20 Initiated Citigroup Buy
Dec-13-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
Nov-07-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-10-19 Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18 Reiterated Stifel Hold
Aug-07-18 Reiterated Stifel Hold
May-08-18 Downgrade Evercore ISI Outperform → In-line
Oct-06-17 Resumed Goldman Sell
Aug-17-17 Initiated Evercore ISI Outperform
Aug-09-17 Reiterated Stifel Hold
Mar-10-17 Downgrade Goldman Neutral → Sell
Dec-28-16 Reiterated BMO Capital Markets Outperform
Dec-27-16 Reiterated Leerink Partners Mkt Perform
View All

Ionis Pharmaceuticals Inc Stock (IONS) Latest News

pulisher
Mar 19, 2025

Familial Chylomicronemia Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 19, 2025
pulisher
Mar 18, 2025

Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

Ionis Pharmaceuticals at UBS Virtual CNS Day: Neurology Pipeline Insights By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 17, 2025

Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace

Mar 17, 2025
pulisher
Mar 14, 2025

IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Retinitis Pigmentosa Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics - Barchart

Mar 14, 2025
pulisher
Mar 14, 2025

Ionis Pharmaceuticals CEO Monia sells $4,524 in stock By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Charles Schwab Investment Management Inc. Purchases 38,420 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Chief Executive Officer Monia Brett P sold $4,525 worth of shares (140 units at $32.32), decreasing direct ownership by 0.08% to 180,980 units (SEC Form 4) - Quantisnow

Mar 13, 2025
pulisher
Mar 13, 2025

Ionis Pharmaceuticals CEO Monia sells $4,524 in stock - Investing.com India

Mar 13, 2025
pulisher
Mar 12, 2025

Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License - Citeline News & Insights

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals at Barclays Conference: Strategic Growth and Partnerships By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL

Mar 12, 2025
pulisher
Mar 12, 2025

Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL

Mar 12, 2025
pulisher
Mar 12, 2025

Ono partners with Ionis for sapablursen - The Pharma Letter

Mar 12, 2025
pulisher
Mar 12, 2025

Ono pays $280M to license Ionis rare disease drug - BioPharma Dive

Mar 12, 2025
pulisher
Mar 12, 2025

Oppenheimer maintains Outperform on Ionis, $78 target By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - MSN

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono - Zacks Investment Research

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $47.00 by Analysts at JPMorgan Chase & Co. - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera - Quantisnow

Mar 11, 2025
pulisher
Mar 11, 2025

Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera - Bluefield Daily Telegraph

Mar 11, 2025
pulisher
Mar 11, 2025

What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Massive $940M Deal: Ionis Partners with Ono on Breakthrough Blood Cancer Treatment - StockTitan

Mar 11, 2025
pulisher
Mar 10, 2025

When the Price of (IONS) Talks, People Listen - Stock Traders Daily

Mar 10, 2025
pulisher
Mar 10, 2025

AstraZeneca and Ionis win EU approval for ATTR polyneuropathy - Yahoo Finance

Mar 10, 2025
pulisher
Mar 10, 2025

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy - pharmaphorum

Mar 10, 2025
pulisher
Mar 10, 2025

Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy - Quantisnow

Mar 10, 2025
pulisher
Mar 10, 2025

Ionis gains EU approval for amyloidosis treatment - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Ionis gains EU approval for amyloidosis treatment By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

WAINZUA (Eplontersen) Approved In The EU For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Leigh Syndrome Treatment Market Poised for Substantial Growth - openPR

Mar 10, 2025
pulisher
Mar 09, 2025

23,703 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Proficio Capital Partners LLC - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Principal Financial Group Inc. Has $476,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Truist Financial Corp Sells 501 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 05, 2025

Amalgamated Bank Purchases 335 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Y Intercept Hong Kong Ltd Trims Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Spinal Muscular Atrophy Market Overall Study Report 2025-2032 | - openPR

Mar 04, 2025
pulisher
Mar 03, 2025

Spinal Muscular Atrophy Pipeline 2024: Key Companies, MOA, ROA, - openPR

Mar 03, 2025
pulisher
Mar 02, 2025

Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.00 - MarketBeat

Mar 02, 2025
pulisher
Feb 28, 2025

ARK Investment Management LLC Sells 359,009 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN

Feb 28, 2025
pulisher
Feb 28, 2025

FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Intellia: Balancing in vivo risk with validated targets - BioCentury

Feb 27, 2025
pulisher
Feb 27, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Rhumbline Advisers - Defense World

Feb 27, 2025

Ionis Pharmaceuticals Inc Stock (IONS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):